Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Biotech Startups
>
Beigene
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6261795"]Next big thing? I seriously doubt that. A lot of the data and trials with this company have been or are being done in China. Anyone that knows anything about the Chinese medical system and how the Chinese and government there conduct business there hould question the validity of clinical trials results coming out of China.</p><p><br /></p><p>Besides, AstraZeneca already has a big headstart in the less of target side effects vs. ibrutinib market. Zanibrutinib will be 3rd to market and offer nothing acalabrutinib and ibrutinib don't already. </p><p><br /></p><p>This company and stock are very overvalued. They may be aggressive because they have to be but that won't be enough. It may only get the company on the US government radar. A Chinese company is going to get a lot of scrutiny given the current environment regardless of how they market their products.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6261795"]Next big thing? I seriously doubt that. A lot of the data and trials with this company have been or are being done in China. Anyone that knows anything about the Chinese medical system and how the Chinese and government there conduct business there hould question the validity of clinical trials results coming out of China. Besides, AstraZeneca already has a big headstart in the less of target side effects vs. ibrutinib market. Zanibrutinib will be 3rd to market and offer nothing acalabrutinib and ibrutinib don't already. This company and stock are very overvalued. They may be aggressive because they have to be but that won't be enough. It may only get the company on the US government radar. A Chinese company is going to get a lot of scrutiny given the current environment regardless of how they market their products.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Biotech Startups
>
Beigene
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Biotech Startups
>
Beigene
>